Compare GSK plc (GSK) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Rigetti Computing Inc — how do they compare? GSK plc trades at $52.63 (market cap $101.34B), while Rigetti Computing Inc trades at $14.35 (market cap $5.07B). The key difference: GSK plc is far larger — about 20× Rigetti Computing Inc's market cap, and GSK plc pays a 3.49% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals.
| GSK | RGTI | |
|---|---|---|
Market Cap | $101.34B | $5.07B |
Sector | Health | Technology |
52-Week High | $61.18 | $56.34 |
52-Week Low | $36.20 | $12.90 |
Enterprise Value | $121.95B | $4.66B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Rigetti Computing (RGTI) trades at $14.72, down 8.63% with bearish technical signals. The company shows negative profitability with -2,253.59% net margin and -$216.21M net loss in 2025, though quarterly EPS has beaten expectations. Analyst sentiment remains strong with 85.71% buy ratings and $32.67 consensus target. Recent news highlights quantum computing sector volatility and Rigetti's infrastructure advancements amid ongoing cash burn.
The stock offers high-risk growth potential in quantum computing with significant analyst upside but faces substantial execution risks. Key challenges include persistent losses, cash burn of $22.82M in 2025, and intense sector competition. Investment suitability depends on risk tolerance for pre-revenue technology ventures with long commercialization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
